Peter Forsyth MD

Oncology•Tampa, FL

Neuro-Oncology

Physician

Request Appointment

12902 USF Magnolia DriveTampa, FL 33612
Book by Phone+1(484) 929-2876
Fax+1 813-449-8246

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1988 - 1991
Michael G. DeGroote School of MedicineClass of 1987

Certifications & Licensure

FL State Medical License 2011 - 2027
CT State Medical License 1993 - 1994
American Board of Psychiatry and Neurology Neurology

Clinical Trials

RO4929097 in Treating Patients With Recurrent Invasive Gliomas Start of enrollment: 2011 Jul 01
Terminated
Phase 1
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Start of enrollment: 2009 Oct 01
Unknown status
Phase 3
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Start of enrollment: 2019 Jun 10
COMPLETED
PHASE1
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30
RECRUITING
PHASE2, PHASE3
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
RECRUITING
PHASE1, PHASE2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
RECRUITING
PHASE1, PHASE2
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Start of enrollment: 2023 Jun 06
COMPLETED
EARLY_PHASE1
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Start of enrollment: 2016 May 01
ACTIVE_NOT_RECRUITING
PHASE2
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Start of enrollment: 2023 Aug 22
RECRUITING
PHASE1
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Start of enrollment: 2022 Dec 19
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-04-01
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Sarah A Weiss, Dijana Djureinovic, Wei Wei, Thuy Tran, Matthew Austin
Journal of Clinical Oncology. 2025-03-06
1 citations
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.
Emilie Le Rhun, Lakshmi Nayak, Mary Jane Lim-Fat, Roberta Rudà, Elena Pentsova
Neuro-Oncology. 2025-02-10

Press Mentions

Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Shop TalkOctober 20th, 2019
Join now to see all